Scholarlink

<p>Alopecia associated with use of endocrine therapy is an underreported adverse effect despite its significant impact on a patient’s quality of life. There is a lack of published evidence for the treatment and management of endocrine therapy–induced alopecia (EIA). Current therapeutic strategies for EIA in breast cancer patients primarily include pharmacologic agents for androgenic alopecia given the similar underlying pathophysiology and clinical presentation of hair loss of EIA and other causes of alopecia. This review aims to summarize select prescription and non-prescription agents (i.e., over-the-counter products, nutraceuticals, dietary supplements) that may be used for EIA including general efficacy and safety. Further studies are needed in the breast cancer population to better understand the place in therapy and efficacy of these pharmacologic agents for EIA.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Approaches to management of endocrine therapy–induced alopecia in breast cancer patients

  • 期刊论文

  • 发表日期：

    2025年2月17日

查看全文
  • Michelle Nguyen,
  • Shawna Kraft

摘要

Alopecia associated with use of endocrine therapy is an underreported adverse effect despite its significant impact on a patient’s quality of life. There is a lack of published evidence for the treatment and management of endocrine therapy–induced alopecia (EIA). Current therapeutic strategies for EIA in breast cancer patients primarily include pharmacologic agents for androgenic alopecia given the similar underlying pathophysiology and clinical presentation of hair loss of EIA and other causes of alopecia. This review aims to summarize select prescription and non-prescription agents (i.e., over-the-counter products, nutraceuticals, dietary supplements) that may be used for EIA including general efficacy and safety. Further studies are needed in the breast cancer population to better understand the place in therapy and efficacy of these pharmacologic agents for EIA.